Future trials leading to government approval depend on the grant.
Funding for the Corporation, as previously negotiated, is tracking in accordance with the critical time-flow provided by the funders to us, Groundell said in a letter of comfort to Medizone. At this time, it is envisaged that the first substantial draw-down will be in hand before the end of November 2000. This delay does not indicate any lack of commitment or ability to proceed from the Investor said a statement received from Ed Marshall, Medizone CEO, but is due to a complex related transaction of the Trust that is taking longer to complete than originally anticipated by the Trustee. For the most part, stockholders have been patient, but that patience is running thin for some, if the message boards are to be believed. Medizone conducted trial treatment studies on 8 patients infected with Hepatitis C, under the guidance of Dr. William Hitt, former member of the MXEI board of directors.